Albumin-Based Filler Platform
Next-Generation Injectable Materials for Aesthetic Medicine
AlbuDerm is developing an albumin-based injectable filler candidate platform, currently in preclinical development and intended for future clinical evaluation. Our lead program focuses on an aesthetic medical filler designed to align with established injection workflows and clinical expectations.
Four Value Tiles
Next GenerationBiomaterial Design
AlbuDerm’s platform is built on recombinant human albumin as a scaffold material, aiming to offer tunable mechanical properties, controlled integration, and predictable behavior in tissue.
Clinician OrientedDevelopment
The platform is being designed to fit existing aesthetic injection techniques, product handling preferences, and workflow realities in clinical practice.
A Platform WithMultiple Paths
The albumin scaffold is being explored for aesthetic fillers and additional future applications in regenerative medicine, soft tissue support, and drug delivery, all at a preclinical stage.
Qualityby Design
AlbuDerm follows a structured, stage gated development approach, integrating material science, preclinical testing, and risk based planning ahead of any future clinical evaluation.
Science. Safety. Aesthetics.
AlbuDerm’s mission is to advance aesthetic medicine through albumin-based injectable materials that combine scientific rigor with practical, clinic ready design.No AlbuDerm product is currently approved for clinical use.
ScienceFirst
Grounded in protein engineering and biomaterials research.
ClinicianPartnered
Developed with input from practicing aesthetic clinicians.
PatientCentered
Aiming to support safe, predictable aesthetic outcomes in future clinical use.
FutureFocused
Built as a platform for multiple potential indications.
Development Status
All AlbuDerm programs are currently at the preclinical or conceptual stage.
No AlbuDerm product has been approved by any regulatory authority, and any future clinical evaluation or commercialization will depend on the outcomes of ongoing and future research and regulatory review.